Here are four notes:
1. Researchers studied the use of the vaccine in mice, which laid the groundwork for a single treatment against various “alpha viruses” such as Chikungunya virus.
2. Lead researcher, Michael Diamond, MD, and his colleagues studied mosquito-borne viruses that usually cause only sporadic outbreaks.
3. After screening 60 antibodies against Chikungunya, researchers found 10 antibodies reacted against three or more different viruses that cause arthritis-like symptoms.
4. The National Institute of Health, in part, funded the study.
Dr. Diamond said, “We have more work to do but are encouraged that [this] could be a viable strategy for developing vaccines or treatments against Chikungunya and other related viruses that cause significant disease worldwide.”
More articles on quality & infection control:
Can too much foot traffic in the OR affect patient safety? Study says yes — 5 insights
Copper can help prevent the spread of respiratory viruses, study finds — 5 highlights
68k Texas residents gain access to quality healthcare — 5 notes
